225 related articles for article (PubMed ID: 28838275)
21. Mutation and Methylation Analysis of Circulating Tumor DNA Can Be Used for Follow-up of Metastatic Colorectal Cancer Patients.
Boeckx N; Op de Beeck K; Beyens M; Deschoolmeester V; Hermans C; De Clercq P; Garrigou S; Normand C; Monsaert E; Papadimitriou K; Laurent-Puig P; Pauwels P; Van Camp G; Taly V; Peeters M
Clin Colorectal Cancer; 2018 Jun; 17(2):e369-e379. PubMed ID: 29605591
[TBL] [Abstract][Full Text] [Related]
22. Serrated colorectal cancer: Molecular classification, prognosis, and response to chemotherapy.
Murcia O; Juárez M; Hernández-Illán E; Egoavil C; Giner-Calabuig M; Rodríguez-Soler M; Jover R
World J Gastroenterol; 2016 Apr; 22(13):3516-30. PubMed ID: 27053844
[TBL] [Abstract][Full Text] [Related]
23. Reclassifying colorectal cancer subtypes.
Burki TK
Lancet Oncol; 2015 Dec; 16(16):e591. PubMed ID: 26511645
[No Abstract] [Full Text] [Related]
24. A feasibility study of colorectal cancer diagnosis via circulating tumor DNA derived CNV detection.
Molparia B; Oliveira G; Wagner JL; Spencer EG; Torkamani A
PLoS One; 2018; 13(5):e0196826. PubMed ID: 29791457
[TBL] [Abstract][Full Text] [Related]
25. Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review.
García-Foncillas J; Alba E; Aranda E; Díaz-Rubio E; López-López R; Tabernero J; Vivancos A
Ann Oncol; 2017 Dec; 28(12):2943-2949. PubMed ID: 28945877
[TBL] [Abstract][Full Text] [Related]
26. Liquid Biopsies in Colorectal Cancer: Monitoring Genetic Heterogeneity.
Gargalionis AN; Papavassiliou AG
Trends Cancer; 2017 Mar; 3(3):166-168. PubMed ID: 28718430
[TBL] [Abstract][Full Text] [Related]
27. Use of Circulating Cell-Free DNA to Guide Precision Medicine in Patients with Colorectal Cancer.
Morris VK; Strickler JH
Annu Rev Med; 2021 Jan; 72():399-413. PubMed ID: 33502901
[TBL] [Abstract][Full Text] [Related]
28. Methylated circulating tumor DNA as a biomarker for colorectal cancer diagnosis, prognosis, and prediction.
Nassar FJ; Msheik ZS; Nasr RR; Temraz SN
Clin Epigenetics; 2021 May; 13(1):111. PubMed ID: 34001239
[TBL] [Abstract][Full Text] [Related]
29. New trends in molecular and cellular biomarker discovery for colorectal cancer.
Aghagolzadeh P; Radpour R
World J Gastroenterol; 2016 Jul; 22(25):5678-93. PubMed ID: 27433083
[TBL] [Abstract][Full Text] [Related]
30. Molecular biomarkers for an early diagnosis, effective treatment and prognosis of colorectal cancer: Current updates.
Mahasneh A; Al-Shaheri F; Jamal E
Exp Mol Pathol; 2017 Jun; 102(3):475-483. PubMed ID: 28506769
[TBL] [Abstract][Full Text] [Related]
31. Translating colorectal cancer genetics into clinically useful biomarkers.
Morley-Bunker A; Walker LC; Currie MJ; Pearson J; Eglinton T
Colorectal Dis; 2016 Aug; 18(8):749-62. PubMed ID: 26990814
[TBL] [Abstract][Full Text] [Related]
32. Circulating tumor DNA
Sun X; Li H; Sun M; Yuan Y; Sun L
Future Oncol; 2019 Oct; 15(30):3513-3525. PubMed ID: 31578881
[No Abstract] [Full Text] [Related]
33. Clinical Relevance of Plasma DNA Methylation in Colorectal Cancer Patients Identified by Using a Genome-Wide High-Resolution Array.
Lin PC; Lin JK; Lin CH; Lin HH; Yang SH; Jiang JK; Chen WS; Chou CC; Tsai SF; Chang SC
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1419-27. PubMed ID: 25472652
[TBL] [Abstract][Full Text] [Related]
34. Blood-based biomarkers for diagnosis, prognosis and treatment of colorectal cancer.
Yörüker EE; Holdenrieder S; Gezer U
Clin Chim Acta; 2016 Apr; 455():26-32. PubMed ID: 26797671
[TBL] [Abstract][Full Text] [Related]
35. Implementable assay for monitoring minimum residual disease after radical treatment for colorectal cancer.
Nakano T; Takao S; Dairaku K; Uno N; Low SA; Hashimoto M; Tsuda Y; Hisamatsu Y; Toshima T; Yonemura Y; Masuda T; Eto K; Ikegami T; Fukunaga Y; Niida A; Nagayama S; Mimori K
Cancer Sci; 2024 Jun; 115(6):1989-2001. PubMed ID: 38531808
[TBL] [Abstract][Full Text] [Related]
36. Detection of
Olmedillas-López S; Lévano-Linares DC; Alexandre CLA; Vega-Clemente L; Sánchez EL; Villagrasa A; Ruíz-Tovar J; García-Arranz M; García-Olmo D
World J Gastroenterol; 2017 Oct; 23(39):7087-7097. PubMed ID: 29093617
[TBL] [Abstract][Full Text] [Related]
37. Molecular biomarkers in the diagnostic of patients with colorectal cancer.
Fabišíková K; Behulová RL; Repiska V
Neuro Endocrinol Lett; 2019 Dec; 40(5):215-221. PubMed ID: 32112545
[TBL] [Abstract][Full Text] [Related]
38. DNA Hypermethylation of SHISA3 in Colorectal Cancer: An Independent Predictor of Poor Prognosis.
Tsai MH; Chen WC; Yu SL; Chen CC; Jao TM; Huang CY; Tzeng ST; Yen SJ; Yang YC
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1481-9. PubMed ID: 25968618
[TBL] [Abstract][Full Text] [Related]
39. Circulating Noncoding RNAs Have a Promising Future Acting as Novel Biomarkers for Colorectal Cancer.
Wang JJ; Wang X; Song YX; Zhao JH; Sun JX; Shi JX; Wu ZH; Wang ZN
Dis Markers; 2019; 2019():2587109. PubMed ID: 31275444
[TBL] [Abstract][Full Text] [Related]
40. Methodological, biological and clinical aspects of circulating free DNA in metastatic colorectal cancer.
Spindler KG
Acta Oncol; 2017 Jan; 56(1):7-16. PubMed ID: 28010185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
